As Authorized Generics Proliferate, Benefits Are Unclear

Pharmaceutical manufacturers likely will continue to turn to authorized generics — drugs produced by brand-name drugmakers without the brand label — as they face increased pushback against high drug prices, but payers and patients probably won’t see much benefit as a result, according to industry experts.

“I think we will continue to see authorized generics competing with traditional generics,” says Stacie Dusetzina, Ph.D., associate professor of health policy at Vanderbilt University School of Medicine. “I’m hopeful that we will see fewer signs that they are being used in pay-for-delay types of arrangements or to discourage traditional generic competition.”

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

business-meeting
May 23

Plans Take Wait-and-See Approach to Vendors Promising Help with Weight Loss Medication Costs

READ MORE
iv-bag
May 23

Studies: IRA Will Spur Medicare Biosimilar Adoption — and Shift Costs to Part D Plans

READ MORE
rpm
May 23

Remote Physiologic Monitoring Use Among Medicaid Enrollees Skyrocketed From 2019 to 2021

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today